02 NOVEMBER 2023 14:30:00 CET

Preclinical data of tasquinimod in myelofibrosis awarded oral presentation at ASH 2023

Lund, November 2, 2023 - Active Biotech (NASDAQ STOCKHOLM: ACTI) announced today that two abstracts with preclinical data for tasquinimod in myelofibrosis and myelodysplastic syndrome have been accepted for presentation at the 65th American Society of Hematology Annual Meeting in San Diego, December 9-12, 2023 (ASH 2023). The abstract demonstrating efficacy of tasquinimod in myelofibrosis has been selected for an oral presentation. The accepted abstracts for ASH 2023 were published today, November 2, 2023.

The abstract, entitled *Preclinical studies demonstrating efficacy of tasquinimod in models of advanced myeloproliferative neoplasm (MPN) in blastic phase*, will be presented as an oral presentation by Dr. Warren Fiskus, PhD, MD Anderson Cancer Center, Texas, USA. The abstract is a result of the collaboration between Active Biotech and Professor Kapil Bhalla´s research group at MD Anderson, which primarily aims to clarify tasquinimod's mechanisms and effects in myelofibrosis. Data to be presented demonstrate efficacy of tasquinimod as monotherapy and in combination with frontline therapies in models of advanced myelofibrosis.

In addition, the abstract entitled *Tasquinimod improves erythropoiesis and mitigates bone loss in myelodysplastic mice* will be presented as a poster by Dr. Manja Wobus, University Hospital Dresden, Germany. The abstract comes from our collaboration with Dr Wobus in Dresden, showing the first evidence for an in vivo effect of tasquinimod in a murine model of MDS, by significantly improving red blood cell counts and decreasing bone loss.

"The data to be presented suggest that treatment with tasquinimod has the potential both in monotherapy and in combination with other therapies to have a broad effect on myelofibrosis and MDS. We are very pleased and honored to have the opportunity to present our data at such a prestigious conference as ASH, which shows the external scientific interest in tasquinimod in this disease area," said Helén Tuvesson, CEO of Active Biotech.

Information on the presentations:

Publication Number: 741 Preclinical Studies Demonstrating Efficacy of Tasquinimod in Models of Advanced Myeloproliferative Neoplasm (MPN) in Blastic Phase, Warren Fiskus et al.
Session Name: 631. Myeloproliferative Syndromes and Chronic Myeloid Leukemia: Basic and **Translational:** Stromal-Immune and Signaling Context
Session Date: Monday, December 11, 2023
Session Time: 10:30 AM - 12:00 PM
Presentation Time: 11:00 AM
Room: San Diego Convention Center, Ballroom 20AB

Publication Number: 2798 Tasquinimod Improves Erythropoiesis and Mitigates Bone Loss in Myelodysplastic Mice, Manja Wobus et al.
Session Name: 604. Molecular Pharmacology and Drug Resistance: Myeloid Neoplasms: Poster II
Session Date: Sunday, December 10, 2023
Presentation Time: 6:00 PM - 8:00 PM
Location: San Diego Convention Center, Halls G-H

The abstracts will be available online on **ASH's website** from 09:00 Eastern time (14:00 CET) on November 2, 2023.

For further information, please contact:

Helén Tuvesson, *CEO*, +46 46 19 21 56, **helen.tuvesson@activebiotech.com**
Hans Kolam, *CFO*, +46 46 19 20 44, **hans.kolam@activebiotech.com**

About Active Biotech

Active Biotech AB (publ) (NASDAQ Stockholm: ACTI) is a biotechnology company that deploys its extensive knowledge base and portfolio of compounds to develop first-in-class immunomodulatory treatments for specialist oncology and immunology indications with a high unmet medical need and significant commercial potential. Following a portfolio refocus, the business model of Active Biotech aims to advance projects to the clinical development phase and then further develop the programs internally or pursue in partnership. Active Biotech currently holds three projects in its portfolio: The wholly owned small molecule immunomodulators, tasquinimod and laquinimod, both having a mode of actions that includes modulation of myeloid immune cell function, are targeted towards hematological malignancies and inflammatory eye disorders, respectively. Tasquinimod, is in clinical phase Ib/IIa for treatment of multiple myeloma. Laquinimod is in clinical development for treatment of non-infectious uveitis and a clinical phase I study with a topical ophthalmic formulation has been concluded. Naptumomab, a targeted anti-cancer immunotherapy, partnered to NeoTX Therapeutics, is in a phase Ib/II clinical program in patients with advanced solid tumors. Please visit **www.activebiotech.com** for more information.

About tasquinimod

Tasquinimod is an oral immunomodulatory and anti-angiogenic investigational treatment, that affects the tumor's ability to grow and metastasize. Tasquinimod is developed as a new immunomodulatory treatment for hematological malignances, in the first step multiple myeloma. Tasquinimod has previously been studied as an anti-cancer agent in patients with solid cancers, including a phase III randomized trial in patients with metastatic prostate cancer. The tolerability of tasquinimod is well-characterized based on these previous experiences. Tasquinimod has demonstrated a clear therapeutic potential in preclinical models of multiple myeloma, when used as a single agent and in combination with standard multiple myeloma therapy. A clinical Phase Ib/IIa study is ongoing with tasquinimod in relapsed and refractory multiple myeloma. Tasquinimod ameliorates disease development in preclinical models for myelofibrosis. In February 2022 Active Biotech entered into an exclusive license agreement with Oncode Institute, acting on behalf of Erasmus Universiteit Medisch Centrum (Erasmus MC) to develop and commercialize tasquinimod worldwide in myelofibrosis. A clinical study with tasquinimod in patients with myelofibrosis is planned to start in 2024.

Attachments

Preclinical data of tasquinimod in myelofibrosis awarded oral presentation at ASH 2023